Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile

2026-04-21 · Source: The AI Journal · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Clinical Care & Medical Practice, Medical Specialties & Subspecialties · Depth: Intermediate, short

Summary

Rznomics presented interim clinical data for RZ-001, an RNA editing-based investigational anticancer therapy, at the AACR 2026 meeting on April 19, 2026. The study evaluated RZ-001 in combination with atezolizumab and bevacizumab for patients with hepatocellular carcinoma (HCC) who are refractory to or ineligible for TACE and have not received prior systemic therapy. Data showed a confirmed objective response rate (ORR) of 38.5% and an unconfirmed ORR of 46.2% based on RECIST v1.1 criteria. Using mRECIST criteria, the ORR was 61.5% with a complete response (CR) rate of 23%. Importantly, no Grade 3 or higher adverse events were attributed to RZ-001, indicating a favorable safety profile and encouraging antitumor activity.

Key takeaway

For Research Scientists evaluating novel HCC therapies, Rznomics' RZ-001 data suggests that RNA editing platforms can achieve significant objective response rates and complete responses, particularly when assessed with mRECIST. You should consider the potential of RNA trans-splicing ribozyme technology for developing new treatments, especially given its favorable safety profile in combination with standard immunotherapy.

Key insights

RZ-001, an RNA editing therapy, shows promising efficacy and safety for hepatocellular carcinoma.

Principles

• mRECIST better reflects HCC treatment efficacy than RECIST.
• RNA trans-splicing ribozyme platform has broad clinical applicability.

Method

The study combined RZ-001 with atezolizumab and bevacizumab for HCC patients refractory to TACE or ineligible for prior systemic therapy, evaluating responses via RECIST v1.1 and mRECIST.

In practice

• Consider mRECIST for HCC trial endpoints.
• Explore RNA editing for difficult-to-treat cancers.

Topics

• RZ-001
• Hepatocellular Carcinoma
• RNA Editing Therapy
• RNA Trans-splicing Ribozyme
• AACR 2026

Best for: Research Scientist, Product Manager, Investor

Related on AIssential

• Gene dependency-informed inference of response to targeted cancer therapies — FORGE co-models drug response and gene dependency to predict cancer therapy benefit, improving mechanistic understanding and prediction.
• SPARKing aptamer discovery — SPARK-seq enables high-throughput aptamer discovery and kinetic profiling in native cellular contexts.
• Paper Digest: AACR 2026 Papers & Highlights — The AACR 2026 meeting features 6,000+ papers indexed by Paper Digest for rapid review.
• Combining Bayesian and Frequentist Inference for Laboratory-Specific Performance Guarantees in Copy Number Variation Detection — Combining Bayesian and frequentist inference yields robust, calibrated CNV detection guarantees for clinical diagnostics.
• Parameter-Efficient Subspace Decoupling ViT for Mitigating Multi-Task Negative Transfer in Histological Scoring — Subspace-decoupled ViT with orthogonal adapters mitigates negative transfer in multi-task histological scoring, improving efficiency.
• Using natural language processing to identify emergency department patients with incidental lung nodules requiring follow-up — An NLP pipeline using RoBERTa and spaCy can automate incidental lung nodule follow-up identification from ED CT reports.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.